CGON - NASDAQ

CG Oncology, Inc. Common stock

CGON·NASDAQ

$54.42

-0.85%

HealthcareBiotechnology

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$4.80B

EPS-2.0800

P/E Ratio-26.16

Earnings Date08/07/2026

cgon

Net Cash Provided by Investing Activities

Last Annual Value

-245.82M

3-Year CAGR

-64%

5-Year CAGR

-379%

10-Year CAGR

-119%

Adjust for Inflation

CG Oncology, Inc. Common stock Competitors Analysis of Net Cash Provided by Investing Activities

CGON · NASDAQ

Company	Net Cash Provided by Investing Activities	CAGR 3Y	CAGR 5Y	CAGR 10Y
CG Oncology, Inc. Common stock NASDAQ:CGON	-245.82M	N/A	N/A	N/A
Travere Therapeutics, Inc. NASDAQ:TVTX	27.89M	-20.6%	N/A	10.4%
Ultragenyx Pharmaceutical Inc. NASDAQ:RARE	236.00M	12.0%	N/A	10.1%
Apogee Therapeutics, Inc. NASDAQ:APGE	-179.57M	N/A	N/A	N/A
Tarsus Pharmaceuticals, Inc. NASDAQ:TARS	-42.12M	N/A	N/A	N/A
Disc Medicine, Inc. NASDAQ:IRON	-394.30M	N/A	N/A	N/A
Celcuity Inc. NASDAQ:CELC	-64.08M	N/A	N/A	N/A
Legend Biotech Corporation NASDAQ:LEGN	711.48M	97.2%	N/A	N/A

CG Oncology, Inc. Common stock Fair Value Envelope

CGON · NASDAQ

Our analysis suggests that CGON has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $54.42, this represents a potential HIDDEN relative to our calculated worth for CG Oncology, Inc. Common stock.

HIDDEN

Intrinsic Value

Current Price: $54.42

Related Guides

Blog Categories

Continue your CGON research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.